Skip to main content

Remote Job Finders (RJF)

Biopharma layoffs rise YOY in October but sharply trend down for 2026

October marked the first time this year there was an increase in both the number of biotech and pharma companies trimming their workforces and the number of affected employees when compared to 2025. Still, it’s highly unlikely 2026 layoffs will come close to matching the downsizing seen last year.

Capricor parts ways with 10% of staff as FDA decision on DMD cell therapy nears

Awaiting a decision on Nov. 22 for its embattled Duchenne muscular dystrophy cell therapy deramiocel, Capricor has reduced its workforce by 10% and slowed programs not directly related to deramiocel, the biotech revealed in its third quarter earnings report.

With an approval apiece, the verdict is still out on AbbVie’s and BMS’ twin neuro buys

After emraclidine’s schizophrenia fail and Cobenfy’s laggard launch, it’s too early to know who made the better buy: AbbVie, in its $8.7 billion Cerevel takeover in late 2023, or Bristol Myers Squibb, which spent $14 billion for Karuna just two weeks later.
Scroll to top